Contact

Still Threshold 82 Home About Services Trial Tracker Regulatory Timeline Safety & Risks Contact A careful field guide · September 2026 Ibogaine Clinical Trial News And Pipeline Updates Ibogaine has moved into a more serious development phase, but it remains an unapproved, high-risk investigational compound. The practical question is not simply whether it might help, but whether rigorous clinical trials can establish an acceptable path for safety and efficacy. This is an independent information resource. It distinguishes investigational research from unverified treatment claims and does not treat private or underground settings as equivalent to FDA-authorized clinical research. The development record is still being made: study design, screening, monitoring, and follow-up matter. The starting material What ibogaine is—and what early signals do not yet prove Interest sits at the intersection of an addiction crisis, difficult treatment gaps, and a compound with a complex record of risk. Ibogaine is a naturally occurring psychoactive alkaloid derived from the root bark of the Tabernanthe iboga plant, with historical use in spiritual practices. It is often described as a plant medicine, but that description does not establish a modern medical safety profile. A concise overview of the compound’s background is available through a definition of ibogaine , while the broader ibogaine reference entry notes its pharmacological complexity and legal status. Early anecdotal reports suggest ibogaine may reduce opioid withdrawal symptoms and cravings for extended periods after a single administration. Those reports have driven interest in addiction treatment for opioid addiction and other substance use disorder presentations, including alcohol, cocaine, and methamphetamine use. They remain hypothesis-generating rather than proof of efficacy. Ibogaine’s therapeutic potential may extend beyond opioid addiction, but the same uncertainty applies to neurological disorders and mental h

Contact

Keep the record clear.